Literature DB >> 21159132

Primary pleural epithelioid hemangioendothelioma (EHE)--two cases and review of the literature.

Angeline Lazarus1, Gregory Fuhrer, Christina Malekiani, Sean McKay, John Thurber.   

Abstract

INTRODUCTION: We present two cases with symptoms of progressively worsening cough, dyspnea, decreased exercise tolerance and right-sided back pain in the first case and upper respiratory symptoms characterized by cough and a low grade fever in the second case.
METHODS: Report of two cases.
RESULTS: The initial chest X-ray in both the cases showed pleural effusion. Further imaging with computed tomography of the chest confirmed the effusion in both cases. Thoracentesis was done in both of them revealed an exudative effusion that did not reveal any infection or malignancy. Both cases underwent surgical biopsy and the diagnosis of primary pleural epithelioid hemangioendothelioma was made.
CONCLUSIONS: Both the cases had progressive clinical deterioration despite chemotherapy with Taxol and Bevacizumab in one case and carboplatin, etoposide, and bevacizumab, in the second case. Both developed metastatic disease to lungs and died. Published 2010. This article is a US Government work and is in the public domain in the USA.

Entities:  

Mesh:

Year:  2010        PMID: 21159132     DOI: 10.1111/j.1752-699X.2010.00221.x

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  12 in total

1.  Pleural epithelioid hemangioendothelioma.

Authors:  Aditya Bansal; Mohit Chawla; Paul J Cohen; Jeff S Kwon
Journal:  Lung       Date:  2012-03-06       Impact factor: 2.584

2.  Difficulty of treatment for pleural epithelioid hemangioendothelioma: a report of a case.

Authors:  Masaru Takenaka; Yoshinobu Ichiki; Yusuke Nabe; Yojiro Tsuda; Taiji Kuwata; Yasuhiro Chikaishi; Ayako Hirai; Naoko Imanishi; Kazue Yoneda; Fumihiro Tanaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-05-02

Review 3.  Combination capecitabine and bevacizumab in the treatment of metastatic hepatic epithelioid hemangioendothelioma.

Authors:  Augustine Lau; Steve Malangone; Myke Green; Ambuga Badari; Kathryn Clarke; Emad Elquza
Journal:  Ther Adv Med Oncol       Date:  2015-07       Impact factor: 8.168

Review 4.  Diagnostic and therapeutic challenges in hepatic epithelioid hemangioendothelioma.

Authors:  Akshitkumar M Mistry; D Lee Gorden; Jacob F Busler; Alice C Coogan; Beau S Kelly
Journal:  J Gastrointest Cancer       Date:  2012-12

5.  Epithelioid hemangioendothelioma: evaluation by 18F-FDG PET/CT.

Authors:  Livia Maria Frota Lima; Annie T Packard; Stephen M Broski
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-04-15

6.  Pleural epithelioid hemangioendothelioma: literature summary and novel case report.

Authors:  Julita Salijevska; Robert Watson; Amy Clifford; Andrew I Ritchie; Francisco Mauri; David Adeboyeku
Journal:  J Clin Med Res       Date:  2015-05-08

Review 7.  A rare case of intravascular epithelioid hemangioendothelioma of the cephalic vein treated with surgery and postoperative radiation therapy: a case report and review of the literature.

Authors:  Maria Paola Ciliberti; Raffaella Caponio; Antonio Pascali; Gabriele Matichecchia; Marco Lioce
Journal:  J Med Case Rep       Date:  2015-04-29

Review 8.  Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.

Authors:  Valeriya Semenisty; Inna Naroditsky; Zohar Keidar; Gil Bar-Sela
Journal:  BMC Cancer       Date:  2015-05-13       Impact factor: 4.430

9.  Activity of angiogenesis inhibitors in metastatic epithelioid hemangioendothelioma: a case report.

Authors:  Sumit Gaur; Alireza Torabi; Thomas J O'Neill
Journal:  Cancer Biol Med       Date:  2012-06       Impact factor: 4.248

Review 10.  Epithelioid Hemangioendothelioma as a Model of YAP/TAZ-Driven Cancer: Insights from a Rare Fusion Sarcoma.

Authors:  John M Lamar; Vijeyaluxmy Motilal Nehru; Guy Weinberg
Journal:  Cancers (Basel)       Date:  2018-07-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.